Lorlatinib for first-line treatment of ALK-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced lung cancer (stage IIIB/C or IV) that is ALK-positive, confirmed by a specific test.
- You must not have had any prior cancer treatment for advanced disease, including chemotherapy, targeted therapy, or immunotherapy.
- You must have at least one measurable tumor outside the brain, not previously irradiated.
- You must be 18 years or older and have good organ function (bone marrow, pancreas, kidneys, liver).
- You must be willing to provide a tumor tissue sample (if not already available, a new biopsy is needed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies (lorlatinib and sacituzumab tirumotecan) as first treatment for advanced non-small cell lung cancer with an ALK gene change. The goal is to see if the combination works better than current treatments and to use a simple blood test to guide therapy.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This study tests an experimental pill for people with a specific type of lung cancer. The trial will see if the drug is safe and if it helps shrink tumors.
This study tests a new drug called NXP900 in combination with lorlatinib for people with ALK-positive lung cancer who have already been treated with lorlatinib and tolerated it well. The goal is to see if this combination is safe and effective.
This study looks at different ways to manage high cholesterol (hyperlipidemia) that happens as a side effect of the drug lorlatinib, which is used to treat ALK-positive lung cancer. Participants will receive additional cholesterol-lowering medicines or strategies, and the study aims to find the best way to keep cholesterol in check while continuing effective cancer treatment.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
Hear when a new ALK-positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.